Table 1.
Characteristics of included studies.
| Authors | Year | Country | Population | Stage | Follow-up months | Subjects | male(%) | Age | Assay | sample | Design | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fan, S. | 2019 | China | SCLC | NALC | 60 | 82 | 81.7 | 60 (28–82) | IA | Plssma | RS | 3 |
| Minglei, Y. | 2019 | China | NSCLC | NALC | 24 | 376 | 60.6 | 58 (27–81) | IA | Plssma | RCT | 8 |
| Hou, C. | 2019 | China | NSCLC | NALC | 13.2 | 395 | 60.0 | 61 (35–81) | IA | Plssma | PCS | 6 |
| Huagang, L. | 2019 | China | NSCLC | NALC | 42 | 456 | 69.7 | 65 (56–69) | IA | Plssma | RS | 4 |
| Edyta I. W. | 2018 | Poland | LC | ALC | 30 | 95 | 75.0 | 67 (40–81) | IA | Plssma | PCS | 6 |
| Cuicui, Z. | 2018 | China | SCLC | NALC | 60 | 160 | 80.6 | 59 (23–83) | IA | Plssma | RS | 3 |
| Wenwen, S. | 2017 | China | NSCLC | ALC | 56 | 785 | 60.0 | ≥65 (41.6%) | IA | Plssma | PCS | 5 |
| Kaoru, S. | 2017 | Japan | NSCLC | ALC | 60 | 237 | 59.1 | 69 ± 9.7 | IA | Plssma | PCS | 7 |
| Zhu, L.-R. | 2016 | China | SCLC | NALC | 60 | 74 | 77.0 | 57 (42–80) | IA | Plssma | PCS | 6 |
| Magdalena, Z. | 2016 | Poland | NSCLC | NALC | 11.5 | 52 | 38.5 | 63 (58–70) | IA | Plssma | PCS | 7 |
| Koichi, F. | 2015 | Japan | NSCLC | ALC | 60 | 247 | 61.5 | 69 (31–85) | IA | Plssma | PCS | 6 |
| Yuezhen, W. | 2015 | China | NSCLC | NALC | 60 | 1931 | 70.0 | ≥65 (39.9%) | ELISA | Plssma | RS | 5 |
| Tuba, I. | 2015 | Turkey | LC | ALC | 60 | 72 | 77.8 | ≥60 (37.5%) | IA | Plasma | PCS | 6 |
| Ge, L.-P. | 2014 | China | NSCLC | NALC | 36 | 82 | 67.0 | 64 (44–72) | IA | Plasma | PCS | 6 |
| Heguo, J. | 2014 | China | NSCLC | ALC | 36 | 184 | 45.2 | ≥60 (34.1%) | IA | Plasma | PCS | 5 |
| Zhang, P.-P. | 2013 | China | NSCLC | NALC | 60 | 232 | 64.2 | 61 (30–86) | IA | Plasma | PCS | 6 |
| Cihan, A. | 2012 | Austria | LC | NALC | 24 | 182 | 56.5 | 62 (52–68) | IA | Plasma | PCS | 7 |
| Katsuhiro, M. | 2011 | Japan | NSCLC | NALC | 60 | 99 | 71.8 | 72 (35–88) | ELISA | Plasma | PCS | 6 |
| Altiay, G. | 2007 | Turkey | LC | ALC | 78 | 78 | 93.6 | 61 (37–82) | ELISA | Plasma | PCS | 7 |
SCLC, small cell lung cancer; NSCLC, non-small-cell lung cancer; LC, lung cancer; NALC, non-advanced lung cancer; ALC, advanced lung cancer; IA, immunoturbidimetric assay; ELISA, enzyme-linked immunosorbent assay; RS, retrospecitive study; PCS, prospective cohort study; RCT, randomized controlled trial.